Tumor Therapy Strategies Based on Microenvironment‐Specific Responsive Nanomaterials
Source abstract
Abstract
Abstract The tumor microenvironment (TME) is a complex and variable region characterized by hypoxia, low pH, high redox status, overexpression of enzymes, and high‐adenosine triphosphate concentrations. In recent years, with the continuous in‐depth study of nanomaterials, more and more TME‐specific response nanomaterials are used for tumor treatment. However, the complexity of the TME causes different types of responses with various strategies and mechanisms of action. Aiming to systematically demonstrate the recent advances in research on TME‐responsive nanomaterials, this work summarizes the characteristics of TME and outlines the strategies of different TME responses. Representative reaction types are illustrated and their merits and demerits are analyzed. Finally, forward‐looking views on TME‐response strategies for nanomaterials are presented. It is envisaged that such emerging strategies for the treatment of cancer are expected to exhibit dramatic trans‐clinical capabilities, demonstrating the extensive potential for the diagnosis and therapy of cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Forest Plant Ecology Ministry of Education College of Chemistry Chemical Engineering and Resource Utilization Northeast Forestry University Harbin 150040 China
School of Chemistry and Chemical Engineering Harbin Institute of Technology Harbin 150001 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Heilongjiang Province · Fundamental Research Funds for the Central Universities
References (100+)
Show source-provided references
1. 10.3390/ijms1807158610.3390/ijms18071586 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. 10.1002/asia.20220049810.1002/asia.202200498 ↗
4. 10.1016/j.actbio.2019.09.00910.1016/j.actbio.2019.09.009 ↗
5. 10.1016/j.biomaterials.2020.11983510.1016/j.biomaterials.2020.119835 ↗
6. 10.1016/j.apsb.2017.09.00310.1016/j.apsb.2017.09.003 ↗
7. 10.1016/j.cclet.2020.02.03210.1016/j.cclet.2020.02.032 ↗
8. 10.1002/bjs.1111510.1002/bjs.11115 ↗
9. 10.1016/j.jconrel.2021.02.03010.1016/j.jconrel.2021.02.030 ↗
10. 10.3390/molecules2401000410.3390/molecules24010004 ↗
11. 10.1007/s40843-019-1183-010.1007/s40843-019-1183-0 ↗
12. 10.1002/adfm.20200807810.1002/adfm.202008078 ↗
13. 10.3390/molecules2518414810.3390/molecules25184148 ↗
14. 10.1039/D0TB00649A10.1039/D0TB00649A ↗
15. 10.1016/j.semcancer.2019.08.03010.1016/j.semcancer.2019.08.030 ↗
16. 10.3390/medicina5601001510.3390/medicina56010015 ↗
17. 10.1002/marc.20180091710.1002/marc.201800917 ↗
18. 10.1002/adhm.20130061310.1002/adhm.201300613 ↗
19. 10.1002/marc.20200039410.1002/marc.202000394 ↗
20. 10.3390/ph1306011310.3390/ph13060113 ↗
21. 10.1093/annonc/mdw16810.1093/annonc/mdw168 ↗
22. 10.1002/jcp.2742510.1002/jcp.27425 ↗
23. 10.3389/fphar.2018.0123010.3389/fphar.2018.01230 ↗
24. 10.1016/j.nantod.2020.10085110.1016/j.nantod.2020.100851 ↗
25. 10.1016/j.jconrel.2019.12.04110.1016/j.jconrel.2019.12.041 ↗
26. 10.1038/nbt110910.1038/nbt1109 ↗
27. 10.1053/j.semnuclmed.2014.10.00210.1053/j.semnuclmed.2014.10.002 ↗
28. 10.2147/IJN.S19204810.2147/IJN.S192048 ↗
29. Vaupel P. · Cancer Res. · 1991 · 51 · 3316
30. 10.1021/cr500463410.1021/cr5004634 ↗
31. 10.1016/j.biomaterials.2019.11957810.1016/j.biomaterials.2019.119578 ↗
32. 10.1016/j.addr.2011.09.00610.1016/j.addr.2011.09.006 ↗
33. 10.1021/acsnano.0c0437010.1021/acsnano.0c04370 ↗
34. 10.1021/cm503304p10.1021/cm503304p ↗
35. 10.1002/advs.20190213710.1002/advs.201902137 ↗
36. 10.1002/path.397810.1002/path.3978 ↗
37. 10.1039/C6RA24979E10.1039/C6RA24979E ↗
38. 10.1038/nnano.2016.7210.1038/nnano.2016.72 ↗
39. 10.1039/C4CC05878J10.1039/C4CC05878J ↗
40. 10.1016/j.nantod.2019.03.00710.1016/j.nantod.2019.03.007 ↗
41. 10.1002/adfm.20190795410.1002/adfm.201907954 ↗
42. 10.1155/2013/97291310.1155/2013/972913 ↗
43. 10.1016/j.biomaterials.2009.01.02610.1016/j.biomaterials.2009.01.026 ↗
44. 10.1016/j.semcancer.2013.08.00710.1016/j.semcancer.2013.08.007 ↗
45. 10.1021/acsnano.1c0107710.1021/acsnano.1c01077 ↗
46. 10.1021/acs.nanolett.8b0390510.1021/acs.nanolett.8b03905 ↗
47. 10.1021/acsnano.8b0938710.1021/acsnano.8b09387 ↗
48. 10.1007/978-981-32-9620-6_210.1007/978-981-32-9620-6_2 ↗
49. 10.1016/j.addr.2012.01.00210.1016/j.addr.2012.01.002 ↗
50. 10.3389/fonc.2019.0137010.3389/fonc.2019.01370 ↗
51. 10.1093/glycob/cwv09710.1093/glycob/cwv097 ↗
52. 10.1016/j.biomaterials.2016.04.03910.1016/j.biomaterials.2016.04.039 ↗
53. 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 ↗
54. 10.1097/00062752-200303000-0000710.1097/00062752-200303000-00007 ↗
55. 10.1016/j.semcdb.2007.05.01110.1016/j.semcdb.2007.05.011 ↗
56. 10.1016/j.biopha.2020.11097810.1016/j.biopha.2020.110978 ↗
57. Tao X. · Acta Physiol. Scand. · 2021 · 73 · 197
58. 10.1039/D0SC03093G10.1039/D0SC03093G ↗
59. 10.1002/ppsc.20200014310.1002/ppsc.202000143 ↗
60. 10.1016/j.actbio.2021.09.01010.1016/j.actbio.2021.09.010 ↗
61. 10.1371/journal.ppat.100256110.1371/journal.ppat.1002561 ↗
62. 10.1158/0008-5472.CAN-19-380710.1158/0008-5472.CAN-19-3807 ↗
63. 10.1371/journal.pone.000259910.1371/journal.pone.0002599 ↗
64. 10.1038/s41588-018-0318-210.1038/s41588-018-0318-2 ↗
65. Wang M. M. · Chem. J. Chin. Univ. · 2021 · 42 · 3071
66. 10.18632/oncotarget.2589110.18632/oncotarget.25891 ↗
67. 10.1002/cbic.20180043810.1002/cbic.201800438 ↗
68. 10.3390/cancers1211329410.3390/cancers12113294 ↗
69. 10.1021/jacs.0c1024510.1021/jacs.0c10245 ↗
70. 10.1039/C9RA00951E10.1039/C9RA00951E ↗
71. 10.1021/jacs.5b0409710.1021/jacs.5b04097 ↗
72. 10.1021/acsnano.8b0978610.1021/acsnano.8b09786 ↗
73. 10.1016/j.ijrobp.2007.11.03410.1016/j.ijrobp.2007.11.034 ↗
74. 10.1117/1.JBO.20.3.03600410.1117/1.JBO.20.3.036004 ↗
75. 10.1021/acsami.8b0594410.1021/acsami.8b05944 ↗
76. 10.1039/C8QM00309B10.1039/C8QM00309B ↗
77. 10.1016/j.biomaterials.2020.12009310.1016/j.biomaterials.2020.120093 ↗
78. 10.1021/acs.nanolett.8b0272010.1021/acs.nanolett.8b02720 ↗
79. 10.1021/acs.nanolett.0c0004710.1021/acs.nanolett.0c00047 ↗
80. 10.1186/s12943-019-1089-910.1186/s12943-019-1089-9 ↗
81. 10.1039/D0BM00678E10.1039/D0BM00678E ↗
82. 10.1002/ppsc.20210004810.1002/ppsc.202100048 ↗
83. 10.1021/acsami.9b1811210.1021/acsami.9b18112 ↗
84. 10.1016/j.carbpol.2021.11861110.1016/j.carbpol.2021.118611 ↗
85. 10.1016/j.biomaterials.2021.12082210.1016/j.biomaterials.2021.120822 ↗
86. Wanandi S. I. · Malays. J. Med. Sci. · 2018 · 25 · 710.21315/mjms2018.25.3.2 ↗
87. 10.1016/j.nantod.2018.08.00710.1016/j.nantod.2018.08.007 ↗
88. 10.1021/bm400511310.1021/bm4005113 ↗
89. 10.1002/adma.20120229610.1002/adma.201202296 ↗
90. 10.1002/mabi.20130033710.1002/mabi.201300337 ↗
91. 10.1002/adma.20110151610.1002/adma.201101516 ↗
92. 10.1021/acsami.5b0147310.1021/acsami.5b01473 ↗
93. 10.1016/j.msec.2017.03.20110.1016/j.msec.2017.03.201 ↗
94. 10.1016/j.jconrel.2007.06.00710.1016/j.jconrel.2007.06.007 ↗
95. 10.1016/j.jconrel.2011.12.00210.1016/j.jconrel.2011.12.002 ↗
96. 10.1021/am800042v10.1021/am800042v ↗
97. 10.1016/j.actbio.2015.08.01810.1016/j.actbio.2015.08.018 ↗
98. 10.1016/j.carbpol.2020.11609310.1016/j.carbpol.2020.116093 ↗
99. 10.3390/pharmaceutics1306089510.3390/pharmaceutics13060895 ↗
100. 10.1016/j.ajps.2019.10.00110.1016/j.ajps.2019.10.001 ↗